Table 1.
Patient characteristics at baseline and at 5 years, in patients with available data*
| Cross-sectional cohort (n = 254) | Prospective cohort (n = 427) | |
|---|---|---|
| Baseline | ||
| Female, no. (%) | 173 (68.1) | 283 (66.3) |
| Age at symptom onset, median (IQR) years | 59.2 (48.4–70.6) | 53.3 (42.6–70.5) |
| HAQ score, median (IQR) | 0.88 (0.25–1.50) | 0.75 (0.25–1.38) |
| RF+, no. (%) | 71 (28.0) | 113 (26.5) |
| Anti-CCP+, no. (%) | 88 (34.6) | 125 (29.3) |
| No. of tender joints, median (IQR) | 3 (1–8) | 8 (3–16) |
| No. of swollen joints, median (IQR) | 3 (1–8) | 6 (2–14) |
| Shared epitope alleles, no. (%) | ||
| 0 | 79 (48.5) | 155 (39.4) |
| 1 | 63 (38.6) | 181 (46.1) |
| 2 | 21 (12.9) | 57 (14.5) |
| 5 years | ||
| No. of tender joints, median (IQR) | – | 0 (0–4) |
| No. of swollen joints, median (IQR) | – | 0 (0–2) |
| HAQ score, median (IQR) | – | 0.75 (0.25–1.5) |
| Treated with DMARD or steroid by 5 years, no. (%) | – | 257 (60.2) |
| Satisfied ACR criteria for RA by year 5, no. (%) | – | 311 (72.8) |
| Symptom duration at baseline, median (IQR) months | 5 (3–10) | 5 (2–12) |
*
IQR = interquartile range; HAQ = Health Assessment Questionnaire; RF = rheumatoid factor; anti-CCP = anti–cyclic citrullinated peptide antibody; DMARD = disease-modifying antirheumatic drug; ACR = American College of Rheumatology; RA = rheumatoid arthritis.